Exodus Point Capital Management, LP Pacira Bio Sciences, Inc. Transaction History

Exodus Point Capital Management, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$27.7 - $35.48 $330,627 - $423,489	11,936 Added 81.16%	26,643 $779,000
Q3 2023 Nov 09, 2023	SELL	$30.68 - $40.09 $273,297 - $357,121	-8,908 Reduced 37.72%	14,707 $451,000
Q2 2023 Aug 10, 2023	BUY	$36.12 - $47.5 $3,539 - $4,655	98 Added 0.42%	23,615 $946,000
Q1 2023 May 11, 2023	SELL	$35.53 - $43.38 $1.14 Million - $1.39 Million	-32,097 Reduced 57.71%	23,517 $960,000
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $2.12 Million - $3.2 Million	55,614 New	55,614 $2.15 Million
Q3 2022 Nov 10, 2022	SELL	$51.24 - $58.89 $874,615 - $1.01 Million	-17,069 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$51.49 - $81.64 $878,882 - $1.39 Million	17,069 New	17,069 $995,000
Q4 2020 Feb 16, 2021	SELL	$50.47 - $66.26 $614,371 - $806,582	-12,173 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$51.97 - $63.0 $632,630 - $766,899	12,173 New	12,173 $732,000
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $697,702 - $1.25 Million	-24,567 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$36.31 - $46.83 $39,723 - $51,232	1,094 Added 4.66%	24,567 $1.11 Million
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $873,135 - $1.1 Million	-24,485 Reduced 51.06%	23,473 $894,000
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $1.75 Million - $2.3 Million	47,958 New	47,958 $2.09 Million
Q1 2019 May 15, 2019	SELL	$36.47 - $42.17 $283,955 - $328,335	-7,786 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$41.31 - $52.16 $321,639 - $406,117	7,786 New	7,786 $335,000

302

51.6M

378K

1.53M

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $712M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.